ArticleFrontiers in oncology2021

The Therapeutic Effectiveness of Neoadjuvant Trastuzumab Plus Chemotherapy for HER2-Positive Breast Cancer Can Be Predicted by Tumor-Infiltrating Lymphocytes and PD-L1 Expression.

Mao Shang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.